TechMARK movers: SkyePharma up on Flutiform

Shareholders in drug developer SkyePharma received a pick-me-up after the company said that its new drug application for its lead development product, Flutiform, has been accepted for review by the US Food and Drug Administration. As a result, an amount of $2m us due to SkyePharma, from which the filing fee of $1.2m will be deducted.Wirelss equipment tester Anite said operating profit for the year ended 30 April was in line with expectations. Both Wireless and Travel reported operating profits ahead of last year with the businesses benefiting from strong cost control and favourable currency movements. Divisional trends were in line with those reported at the time of the company's interim management statement in February.Anite also said it is making good progress with the recruitment of a new finance director.FTSE TechMARK - RisersInion (IIN) 1.00p +100.00%Alizyme (AZM) 6.75p +21.62%Intec Telecom (ITL) 63.00p +19.43%Skyepharma (SKP) 186.00p +9.09%KCOM Group (KCOM) 27.00p +6.93%Phytopharm (PYM) 5.75p +6.88%Kofax (KFX) 128.00p +4.92%Antisoma (ASM) 29.75p +3.48%Ark Therapeutics (AKT) 53.50p +2.88%Imagination Technologies (IMG) 102.00p +2.00%FTSE TechMARK - FallersRenovo Group (RNVO) 29.50p -4.84%Puricore (PURI) 11.25p -4.26%Biocompatibles International (BII) 163.00p -4.12%Electronic Data Processing (EDP) 47.50p -4.04%Emblaze (BLZ) 36.00p -4.00%Genetix Group (GTX) 50.50p -3.81%Optos (OPTS) 50.00p -3.38%Ricardo Group (RCDO) 199.00p -2.45%Vernalis (VER) 65.00p -1.52%Anite Group (AIE) 33.00p -1.49% Ashoka India Equity Investment Trust Plc